Comparison of Oral Anticoagulants vs. Warfarin for Stroke Prevention in Atrial Fibrillation: A Meta-Analysis Oral Anticoagulants vs. Warfarin in AF: A Meta Analysis
Article Sidebar
Main Article Content
Abstract
Background: Atrial fibrillation (AF) significantly increases the risk of ischemic stroke, necessitating effective anticoagulation therapy. Warfarin has been the standard treatment, but direct oral anticoagulants (DOACs) have emerged as a safer and more effective alternative.
Objective: To compare the efficacy and safety of DOACs versus warfarin in stroke prevention among AF patients.
Methods: A comprehensive literature search was conducted in PubMed, EMBASE, Cochrane Library, Web of Science, and Scopus following PRISMA guidelines. Randomized controlled trials and observational studies comparing DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) with warfarin in AF patients were included. Primary outcomes were ischemic stroke or systemic embolism, and secondary outcomes included all-cause mortality, major bleeding, intracranial hemorrhage (ICH), and gastrointestinal bleeding. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using a random-effects model.
Results: A total of 35 studies involving 172,350 patients were analyzed. DOACs significantly reduced ischemic stroke or systemic embolism (HR: 0.78, 95% CI: 0.72–0.84, p < 0.001) and all-cause mortality (HR: 0.85, 95% CI: 0.79–0.92, p = 0.002). Major bleeding risk was lower (HR: 0.88, 95% CI: 0.80–0.96, p = 0.005), but gastrointestinal bleeding was higher (HR: 1.20, 95% CI: 1.10–1.30, p < 0.001).
Conclusion: DOACs provide superior efficacy and safety in stroke prevention compared to warfarin, despite a higher risk of gastrointestinal bleeding.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, RE-LY Investigators. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. New England Journal of Medicine. 2009;361(12):1139-1151.
Xu ZQ, Xu ZH, Zhang N. Comprehensive systematic review and meta-analysis on anticoagulants and aspirin for stroke prevention in non-valvular atrial fibrillation patients. European Review for Medical & Pharmacological Sciences. 2023 Nov 15;27(22).
Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation. New England Journal of Medicine. 2011;365(11):981-992.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine. 2011;365(10):883-891.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the Efficacy and Safety of New Oral Anticoagulants With Warfarin in Patients With Atrial Fibrillation: A Meta-Analysis of Randomised Trials. The Lancet. 2014;383(9921):955-962.
Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) Versus Warfarin in Patients With Atrial Fibrillation. The American Journal of Cardiology. 2012;110(3):453-460.
Beyer-Westendorf J, Will-O'Connor C. DOACs in the Management of Atrial Fibrillation: A Focus on Safety. Expert Opinion on Drug Safety. 2020;19(8):1025-1035.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation: Management of Patients With Atrial Fibrillation (A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society). Circulation. 2019;140(2).
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s Tool for Assessing Risk of Bias in Randomised Trials. BMJ. 2011;343.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine. 2009;6(7).
Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute. 2014.
Fong KY, Chan YH, Yeo C, Lip GY, Tan VH. Systematic review and meta-analysis of direct oral anticoagulants versus warfarin in atrial fibrillation with low stroke risk. The American Journal of Cardiology. 2023 Oct 1;204:366-76.
Johnson LS, Benz AP, Shoamanesh A, Eikelboom JW, Ezekowitz M, Giugliano RP, Wallentin L, Ruff CT, Lopes RD, Jolly S, Whitlock R. Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient‐Level Meta‐Analysis From COMBINE AF. Journal of the American Heart Association. 2024 Sep 3;13(17):e034758.
Zhang B, Cheng W, Kaisaier W, Gu Z, Zhu W, Jiang Q. Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis. Heliyon. 2023 Nov 3.
Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS. The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation. Annals of Internal Medicine. 2009;151(5):297-305.